Dos Santos José Sebastião, Kemp Rafael, Orquera Alicia Guadalupe Mendoza, Gaspar Alberto Facury, Júnior Jorge Resende Lopes, Queiroz Lucas Tobias Almeida, Avezum Víctor Antônio Peres Alves Ferreira, Ardengh José Celso, Sankarankutty Ajith Kumar, Lima Leonardo Santos
Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP), São Paulo 05508-220, Brazil.
Postgraduate Program, Department of Surgery and Anatomy, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP), São Paulo 05508-220, Brazil.
J Clin Med. 2024 Jan 14;13(2):460. doi: 10.3390/jcm13020460.
The advantages of single-stage treatment of cholecystocholedocholithiasis are well established, but the conditions for carrying out treatment on an outpatient basis require a review of concepts and practices of medical corporations.
To evaluate the practice of treating cholecystocholedocholithiasis by laparoendoscopy on an outpatient basis with cost analysis.
A retrospective study was conducted on patients with cholecystocholedocholithiasis treated by combined laparoscopic cholecystectomy and endoscopic choledocholithotomy from January 2015 to January 2019. After collecting data from physical and digital medical records, the patients were divided into two groups-AR ( = 42)-ambulatory regimen and HR ( = 28)-hospitalization regimen-which were compared in terms of demographic, clinical and treatment variables and their results, as well as in terms of costs.
The mean age of the AR group was lower than that of the HR group and the physical status of the AR patients was better when assessed according to the American Society of Anesthesiologists (ASA) ( = 0.01). There was no difference between groups regarding the risk of choledocholithiasis ( = 0.99). For the AR group, the length of stay was shorter: 11.29 h × 65.21 h ( = 0.02), as was the incidence of postoperative complications assessed by applying the Clavien-Dindo classification: 3 (7.1%) × 11 (39.2%) ( < 0.01). The total mean costs were higher for the HR group (USD 2489.93) than the AR group (USD 1650.98) ( = 0.02).
Outpatient treatment of cholecystocholedocholithiasis by laparoendoscopy is safe and viable for most cases, has a lower cost and can support the reorientation of training and practice of hepatobiliary surgeons.
胆囊胆总管结石一期治疗的优势已得到充分证实,但门诊治疗的实施条件需要对医疗企业的理念和实践进行重新审视。
通过成本分析评估门诊腹腔镜内镜联合治疗胆囊胆总管结石的实践。
对2015年1月至2019年1月接受腹腔镜胆囊切除术和内镜胆总管切开取石术联合治疗的胆囊胆总管结石患者进行回顾性研究。从纸质和电子病历中收集数据后,将患者分为两组——AR组(n = 42)——门诊治疗方案组和HR组(n = 28)——住院治疗方案组——比较两组在人口统计学、临床和治疗变量及其结果方面,以及成本方面的差异。
AR组的平均年龄低于HR组,根据美国麻醉医师协会(ASA)评估,AR组患者的身体状况更好(P = 0.01)。两组在胆总管结石风险方面无差异(P = 0.99)。对于AR组,住院时间更短:11.29小时vs 65.21小时(P = 0.02),应用Clavien-Dindo分类评估的术后并发症发生率也更低:3例(7.1%)vs 11例(39.2%)(P < 0.01)。HR组的总平均成本(2489.93美元)高于AR组(1650.98美元)(P = 0.02)。
对于大多数病例,门诊腹腔镜内镜联合治疗胆囊胆总管结石是安全可行的,成本较低,并且可以支持肝胆外科医生培训和实践的重新定位。